

SCHERING PLOUGH CORP  
Form 8-K  
July 21, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 21, 2008**

**SCHERING-PLOUGH CORPORATION**

(Exact Name of Registrant as Specified in its Charter)

New Jersey  
(State or Other Jurisdiction of  
Incorporation)

1-6571  
(Commission File Number)

22-1918501  
(IRS Employer  
Identification Number)

2000 Galloping Hill Road  
Kenilworth, NJ 07033  
(Address of Principal Executive Office)

Registrant's telephone number, including area code: (908) 298-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

Schering-Plough today issued a press release titled Schering-Plough Reports Financial Results for Second Quarter of 2008 and provided additional supplemental financial data. The press release is furnished as Exhibit 99.1 to this 8-K. The supplemental financial data is furnished as Exhibit 99.2 to this 8-K.

ITEM 8.01 OTHER EVENTS

Terje R. Pedersen, M.D., Professor of Medicine, the lead independent investigator in the SEAS study, today issued a press release titled Results from the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study. The SEAS study investigated the effects of intensive cholesterol lowering with the combination of simvastatin and ezetimibe (marketed as VYTORIN by the Merck/Schering-Plough joint venture) in patients with aortic stenosis. This press release is furnished as Exhibit 99.3 to this 8-K.

The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) today issued a press release titled Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe. CTSU conducted and interpreted an independent analysis of data in the SEAS study, the SHARP (Study of Heart and Renal Protection) study and the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) study. This press release is furnished as Exhibit 99.4 to this 8-K.

---

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

99.1 Press release dated July 21, 2008 titled Schering-Plough Reports Financial Results for Second Quarter of 2008

99.2 Supplemental Financial Data

99.3 Press release dated July 21, 2008 titled Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study

99.4 Press release dated July, 2008 titled Independent Analysis of the SEAS, SHARP and IMPROVE-IT studies of Ezetimibe

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  
Schering-Plough Corporation

By: /s/ Steven H. Koehler  
Steven H. Koehler  
Vice President and Controller  
Date: July 21, 2008

---

Exhibit Index

Exhibit Number	Description
99.1	Press release dated July 21, 2008 titled Schering-Plough Reports Financial Results for Second Quarter of 2008
99.2	Supplemental Financial Data
99.3	Press release dated July 21, 2008 titled Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
99.4	Press release dated July, 2008 titled Independent Analysis of the SEAS, SHARP and IMPROVE-IT studies of Ezetimibe